FY2024 Earnings Forecast for PCRX Issued By Zacks Research

Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Equities research analysts at Zacks Research dropped their FY2024 earnings per share (EPS) estimates for Pacira BioSciences in a research note issued on Tuesday, February 11th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $2.61 per share for the year, down from their previous estimate of $2.63. The consensus estimate for Pacira BioSciences' current full-year earnings is $2.40 per share. Zacks Research also issued estimates for Pacira BioSciences' Q4 2024 earnings at $0.59 EPS, Q1 2025 earnings at $0.63 EPS, Q2 2025 earnings at $0.68 EPS, Q3 2025 earnings at $0.66 EPS, Q4 2025 earnings at $0.68 EPS, FY2025 earnings at $2.66 EPS, Q1 2026 earnings at $0.65 EPS, Q2 2026 earnings at $0.69 EPS, Q3 2026 earnings at $0.67 EPS and FY2026 earnings at $2.83 EPS.

PCRX has been the topic of several other reports. HC Wainwright reiterated a "buy" rating and set a $39.00 target price on shares of Pacira BioSciences in a report on Wednesday, December 4th. Needham & Company LLC boosted their price target on Pacira BioSciences from $22.00 to $30.00 and gave the company a "buy" rating in a report on Monday, January 13th. Barclays cut their price target on Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating on the stock in a report on Tuesday, November 12th. Royal Bank of Canada restated a "sector perform" rating and issued a $18.00 price target on shares of Pacira BioSciences in a report on Tuesday, January 14th. Finally, Truist Financial upgraded Pacira BioSciences from a "sell" rating to a "hold" rating and boosted their price target for the company from $8.00 to $25.00 in a report on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $22.78.

Pacira BioSciences Trading Up 3.9 %

PCRX stock traded up $1.00 during midday trading on Friday, hitting $26.44. 759,715 shares of the company's stock were exchanged, compared to its average volume of 820,797. The stock's fifty day moving average price is $22.13 and its 200-day moving average price is $18.16. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The company has a market cap of $1.22 billion, a PE ratio of -13.02 and a beta of 0.80. Pacira BioSciences has a one year low of $11.16 and a one year high of $31.67.

Institutional Trading of Pacira BioSciences

A number of hedge funds and other institutional investors have recently modified their holdings of PCRX. Truist Financial Corp acquired a new position in Pacira BioSciences during the second quarter worth approximately $423,000. SG Americas Securities LLC increased its position in Pacira BioSciences by 96.4% during the third quarter. SG Americas Securities LLC now owns 25,254 shares of the company's stock worth $380,000 after buying an additional 12,396 shares during the last quarter. CWM LLC increased its position in Pacira BioSciences by 713.6% during the third quarter. CWM LLC now owns 6,517 shares of the company's stock worth $98,000 after buying an additional 5,716 shares during the last quarter. Inspire Investing LLC increased its position in Pacira BioSciences by 122.7% during the third quarter. Inspire Investing LLC now owns 27,474 shares of the company's stock worth $413,000 after buying an additional 15,138 shares during the last quarter. Finally, Wedge Capital Management L L P NC increased its position in Pacira BioSciences by 131.9% during the third quarter. Wedge Capital Management L L P NC now owns 119,447 shares of the company's stock worth $1,798,000 after buying an additional 67,947 shares during the last quarter. Institutional investors and hedge funds own 99.73% of the company's stock.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.